Reaction
Jugular Vein Distension reporting signals
As of the last recalculation, Jugular Vein Distension appears in 566 FAERS reports alongside 15 co-occurring drug terms. The strongest observed disproportionality signal is EPLERENONE (PRR 68.8).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Eplerenone | 23 | 68.8 | 68.9 |
| Metolazone | 19 | 64.3 | 64.4 |
| Isosorbide Dinitrate | 21 | 41.0 | 41.1 |
| Amiodarone Hydrochloride | 12 | 40.2 | 40.3 |
| Digoxin | 69 | 40.1 | 40.2 |
| Epoprostenol | 12 | 34.4 | 34.5 |
| Epoetin Alfa | 9 | 28.4 | 28.4 |
| Sildenafil Powder, | 19 | 20.3 | 20.3 |
| Riociguat | 17 | 19.7 | 19.7 |
| Macitentan | 34 | 19.1 | 19.2 |
| Tolvaptan | 7 | 17.9 | 17.9 |
| Selexipag | 12 | 17.4 | 17.4 |
| Bosentan | 22 | 16.7 | 16.7 |
| Treprostinil | 37 | 11.5 | 11.5 |
| Sacubitril And Valsartan | 32 | 10.7 | 10.7 |